Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibCamillo Porta, Lucia Bonomi, Chiara Paglino et al.|Clinical and Experimental Medicine|2007Cited by 146
Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patientsCamillo Porta, Luciano Mutti, Matteo Zimatore et al.|Lung Cancer|2005Cited by 51
Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.Camillo Porta, B. Rovereto, Lucia Bonomi et al.|PubMed|2007Cited by 35
Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted AgentsCamillo Porta, Lucia Bonomi, Ilaria Imarisio et al.|The Scientific World JOURNAL|2007Cited by 29
Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in ItalyPaolo Bidoli, Angelo Delmonte, Rita Chiari et al.|Annals of Oncology|2016Cited by 19